Phio Pharmaceuticals Announces $1.15M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Benzinga12/20 03:32

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And...

Benzinga12/19 20:50

Phio Pharmaceuticals Announces Publication In Frontiers In Immunology Announces Its Manuscript, Self-Delivering RNAi Immunotherapeutic PH-762 Silences PD-1 To Generate Local And Abscopal Anti-Tumor Efficacy, Has Been Published In The December, 2024...

Benzinga12/12 22:32

Phio Pharmaceuticals Completes Enrollment In Second Cohort In Phase 1b Dose-Escalating Clinical Study

Benzinga11/19 20:48

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

newsfile11/19 20:45

Phio Pharma Shares Are Trading Higher. The Company Reported Q3 Financial Results.

Benzinga11/15 21:36